HMOX1 and triple-A syndrome: Fig 7 shows that rosuvastatin treatment significantly reduced the size of AAA development by 32% compared to vehicle only-treated (2.3±0.2 versus 1.6±0.2 mm, respectively, p<0.04). When total HO enzyme activity was measured in the aortae of vehicle- and rosuvastatin-treated mice, no significant difference was found between the two groups (42.6±19.1 (n = 6) versus 51.2±19.2 pmol CO/h/mg FW (n = 9), respectively, Fig 8).